Global Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.

Press releases published on September 24, 2026

4 hours ago

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Indeterminate GlobeNewswire

4 hours ago

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Indeterminate GlobeNewswire

4 hours ago

PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment

Indeterminate GlobeNewswire

4 hours ago

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Indeterminate GlobeNewswire

5 hours ago

Island Announces $400 Million Series F, Bringing Valuation to $6.4 Billion

Indeterminate GlobeNewswire

5 hours ago

Huagui Group: A Global Player across Two RMB100-Billion Aquatic Markets, with Honghu Lotus Root Ranked No. 1 for Antioxidant Content

Indeterminate GlobeNewswire

5 hours ago

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Indeterminate GlobeNewswire

5 hours ago

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Indeterminate GlobeNewswire

5 hours ago

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Indeterminate GlobeNewswire

5 hours ago

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Indeterminate GlobeNewswire

6 hours ago

Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000

Indeterminate GlobeNewswire

7 hours ago

Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric Disorders

Indeterminate GlobeNewswire

8 hours ago

BOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the Mesa

Indeterminate GlobeNewswire

8 hours ago

Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

Indeterminate GlobeNewswire

8 hours ago

Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment

Indeterminate GlobeNewswire

8 hours ago

フレン・ヘルス、次世代の創傷治療用組換え酵素の製造に、AGCバイオロジクスを選定

Indeterminate GlobeNewswire

8 hours ago

Flen Health, 차세대 상처 치료제용 재조합 효소 생산 위해 AGC Biologics 선정

Indeterminate GlobeNewswire

8 hours ago

Flen Health Memilih AGC Biologics untuk Mengeluarkan Enzim Rekombinan bagi Rawatan Luka Generasi Baharu

Indeterminate GlobeNewswire

8 hours ago

Flen Health 选择 AGC Biologics 生产新一代伤口治疗用重组酶

Indeterminate GlobeNewswire

8 hours ago

Flen Health 選擇 AGC Biologics 生產用於新一代傷口治療的重組酶

Indeterminate GlobeNewswire